Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 168,581,136
  • Shares Outstanding, K 5,666,593
  • Annual Sales, $ 58,496 M
  • Annual Income, $ 2,119 M
  • 60-Month Beta 0.68
  • Price/Sales 2.89
  • Price/Cash Flow 10.10
  • Price/Book 1.94
Trade PFE with:

Options Overview Details

View History
  • Implied Volatility 20.92% ( -1.31%)
  • Historical Volatility 17.80%
  • IV Percentile 5%
  • IV Rank 17.76%
  • IV High 33.73% on 10/27/23
  • IV Low 18.16% on 05/13/24
  • Put/Call Vol Ratio 0.43
  • Today's Volume 58,811
  • Volume Avg (30-Day) 109,567
  • Put/Call OI Ratio 1.08
  • Today's Open Interest 3,104,359
  • Open Int (30-Day) 2,941,684

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 0.63
  • Number of Estimates 7
  • High Estimate 0.76
  • Low Estimate 0.50
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +470.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.14 +5.69%
on 09/03/24
30.35 -2.01%
on 09/19/24
+0.94 (+3.26%)
since 08/19/24
3-Month
27.07 +9.86%
on 06/27/24
31.54 -5.71%
on 07/30/24
+2.33 (+8.50%)
since 06/18/24
52-Week
25.20 +18.02%
on 04/26/24
34.11 -12.81%
on 10/03/23
-4.25 (-12.50%)
since 09/19/23

Most Recent Stories

More News
Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?

Pfizer PFE stock has risen 7.3% in the past three months compared with an increase of 2.9% for the industry. The stock has also outperformed the sector as well as the S&P 500, as seen in the chart below.PFE...

PFE : 29.73 (-0.07%)
NVO : 134.91 (+2.16%)
LLY : 913.54 (+0.95%)
ABRYSVOâ„¢: Pfizer Canada's Newly Publicly Funded Vaccine a Step Towards National RSV Prevention in Older Adults

/CNW/ - Today, Pfizer Canada ULC announced that ABRYSVOâ„¢ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus...

PFE : 29.73 (-0.07%)
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell lung cancer...

AZN : 79.09 (+0.65%)
PFE : 29.73 (-0.07%)
MRK : 117.04 (-1.35%)
LLY : 913.54 (+0.95%)
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer

Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population.The regulatory body approved Kisqali in combination with an aromatase inhibitor (AI) for...

NVS : 116.28 (+0.27%)
PFE : 29.73 (-0.07%)
LLY : 913.54 (+0.95%)
3 Magnificent Dividend Stocks With Yields Above 5% to Buy Now and Hold Forever

After underperforming over the past few years, these stocks offer huge dividend yields that could keep rising throughout your retirement.

WPC : 63.28 (-0.39%)
VZ : 43.54 (-0.77%)
PFE : 29.73 (-0.07%)
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030

These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.

MRK : 117.04 (-1.35%)
PFE : 29.73 (-0.07%)
MRNA : 69.25 (-0.87%)
VRTX : 480.04 (+1.24%)
VKTX : 67.20 (+4.27%)
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%

Novartis NVS announced positive data on breast cancer drug Kisqali (ribociclib) from the late-stage study, NATALEE.This late-breaking data from this four-year post-hoc analysis was presented at the European...

NVS : 116.28 (+0.27%)
PFE : 29.73 (-0.07%)
LLY : 913.54 (+0.95%)
BAYRY : 8.0965 (+3.93%)
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)

Telemedicine once seemed like it was going to revolutionize healthcare.

LLY : 913.54 (+0.95%)
PFE : 29.73 (-0.07%)
NVO : 134.91 (+2.16%)
TDOC : 9.35 (+2.86%)
AMZN : 189.47 (+1.63%)
NVDA : 119.03 (+4.99%)
SFIX : 4.16 (+0.48%)
VKTX : 67.20 (+4.27%)
ALT : 7.65 (+2.96%)
RHHBY : 39.5300 (-0.20%)
HIMS : 16.86 (+3.37%)
Lilly Gets FDA Approval for Eczema Drug Ebglyss

Eli Lilly and Company LLY announced that the FDA has granted approval to its IL-13 inhibitor Ebglyss (lebrikizumab) for treating moderate-to-severe atopic dermatitis, also called eczema. Ebglyss is approved...

NVS : 116.28 (+0.27%)
BIIB : 202.31 (+2.39%)
PFE : 29.73 (-0.07%)
LLY : 913.54 (+0.95%)
Smartsheet Nears $8 Billion Buyout Deal with Vista and Blackstone

Private equity giants Vista Equity Partners and Blackstone (BX) are nearing a significant acquisition deal to buy Smartsheet, a collaboration-software company, for around $8 billion. Sources familiar with...

SMAR : 50.82 (-1.61%)
BX : 159.69 (+3.07%)
PFE : 29.73 (-0.07%)
CSCO : 51.49 (+1.82%)
AAL : 11.19 (+1.45%)
ASAN : 12.51 (+4.95%)
EDR : 27.67 (+0.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 30.43
2nd Resistance Point 30.28
1st Resistance Point 30.02
Last Price 29.73
1st Support Level 29.61
2nd Support Level 29.46
3rd Support Level 29.20

See More

52-Week High 34.11
Fibonacci 61.8% 30.71
Last Price 29.73
Fibonacci 50% 29.66
Fibonacci 38.2% 28.60
52-Week Low 25.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar